There is provided an integrated device for wavelength dependent detection of light, comprising: a concentrating element comprising a collecting end and a transmitting end, and configured to collect light incident at the collecting end, and to concentrate the light at the transmitting end; a multimode waveguide forming an extension from a receiving end to a distributing end, and surrounded by a host medium along the extension, wherein the transmitting end is coupled to the receiving end, the waveguide being configured to receive the light from the concentrating element at the receiving end, wherein the waveguide and the host medium are configured to propagate light to form a light pattern at the distributing end, wherein a distribution of the light pattern across the distributing end is dependent on wavelength of the light; a plurality of light sensitive elements arranged such that different light sensitive elements receive different portions of the light pattern at the distributing end for wavelength dependent detection of light.
G01J 1/12 - Photométrie, p. ex. posemètres photographiques par comparaison avec une lumière de référence ou avec une valeur électrique de référence en utilisant des moyens entièrement visuels
G02B 6/12 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
G02B 6/42 - Couplage de guides de lumière avec des éléments opto-électroniques
A radionuclide separating system for separating a 213Bi daughter radionuclide from a 225Ac parent radionuclide, the radionuclide separating system comprising: an inlet for loading a liquid solution comprising the 225Ac parent radionuclide onto a column; the column comprising a sorbent material wherein the sorbent material is capable of interacting with the 225Ac parent radionuclide and 213Bi daughter radionuclide so as to allow selective desorption of the 225Ac parent radionuclide and/or the 213Bi daughter radionuclide at a different moment in time; and an outlet for selectively obtaining the 213Bi daughter radionuclide based on the selective desorption of the 225Ac parent radionuclide and the 213Bi daughter radionuclide, wherein the sorbent material is a carbon-based sorbent material.
C22B 3/24 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques par adsorption sur des substances solides, p. ex. par extraction avec des résines solides
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
3.
NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES
The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and/or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and/or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.
C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The present invention relates to novel compounds of formulae (I) and (III), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and/or PTPN 1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and/or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.
C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
Current application relates to the field of neurodegenerative diseases. Specifically, the present invention relates to screening methods to identify therapeutic candidates for the prevention and/or treatment of Alzheimer's disease. More particularly, said candidates overcome endolysosomal dysfunction resulting from an accumulation of APP-carboxyterminal fragments.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/84 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des composés inorganiques ou le pH
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
6.
MONOGLYCERIDE LIPASE INHIBITORS IN THE TREATMENT OF PANCREATIC CANCER
The invention relates to compositions comprising an inhibitor of MGLL (Monoglyceride Lipase), and an immunotherapy agent for use in the treatment of pancreatic cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The invention relates to chemotherapy agents such as gemcitabine and and inhibitors of UDP-glucose ceramide glucosyltransferase synthase (UGCG) such as miglustat, lucerastat, sinbaglustat, eliglustat, ibiglustat, for use in the treatment of cancers, such as pancreatic cancers.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
The present invention solves the problems of the related art by an interrupted light treatment for plant or crops cultivation with artificial light, with a sudden increase and sudden decrease in light intensity of a horticulture light appliance at a light spectrum suitable or optimal for the plant growth, while saving illumination energy of the lighting device. In accordance with the purpose of the invention, as embodied and broadly described herein, the invention is broadly drawn to a plant cultivation method whereby the plants are alternately under periods of pulsed light irradiating during an irradiation period followed by a non-irradiation (dark) period and whereby the light irradiation period pulses have an even or uneven pulse width between 1 to 60 seconds of irradiation, with a duty cycle of minimum 70 %, and a 0,1 to 15 seconds episodes of low-or non-irradiation in between the light irradiation pulses.
22 in respiratory produce, such as on fruits that have a "core" of several small seeds or fruits surrounded by a tough membrane or such as fruits from the plant family Rosacea.
G01N 21/39 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant des lasers à longueur d'onde réglable
G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
Provided herein is a re-scan optical system (100) for obtaining an image of a sample (190) comprising: —a moveable mirror (180) configured for: —scanning an illumination light, IL (130), as an IL pattern (126) over and/or through the sample (190), —de-scanning sample light, SL (160), from the sample (190), the SL (160) caused by the IL pattern (126), and —re-scanning the de-scanned SL as an SL pattern (152) over an imaging plane (154) of an imaging system (156), wherein light paths incident with (132a, 162a, 166a) or reflected by (134a, 164a, 168a) the moveable mirror (180) pass through one (L2-3) or two (L2, L3) moveable mirror focusing, MMF, lenses, wherein an MMF lens (L2, L3, L2-3) is a lens or lens group separated from the moveable mirror (180) by its focal length.
A system comprises at least two photovoltaic modules each comprising a respective module area being substantially perpendicular to the thickness of the corresponding photovoltaic module. Each of the at least two module areas comprises at least one of two first sides being substantially perpendicular to the thickness of the corresponding photovoltaic module and/or two second sides being substantially perpendicular to the thickness of the corresponding photovoltaic module. In this context, the at least two module areas are arranged in a substantially parallel manner with respect to each other and are shifted with respect to each other in an extension direction of the system. In addition to this, the at least two module areas are arranged in a staggering or alternating or ascending or descending manner with respect to an extension plane in the extension direction of the system.
Present invention concerns a broadband short-wave infrared (SWIR) phosphor-conversion light emitting device including the same are disclosed in this application. More particularly the invention relates to the use of a material containing lead-halide-perovskite-comprising microcrystals, for instance in the form of films or coatings, as a phosphor-conversion material, for instance in a sheet form or as a material, for instance in the form of a sheet, as a layer or a coating, for light emission in the SWIR or the second near infrared wavelength region (NIR-II) between 900nm and 1600nm.
H01L 33/50 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les éléments du boîtier des corps semi-conducteurs Éléments de conversion de la longueur d'onde
H01L 31/12 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails structurellement associés, p.ex. formés dans ou sur un substrat commun, avec une ou plusieurs sources lumineuses électriques, p.ex. avec des sources lumineuses électroluminescentes, et en outre électriquement ou optiquement couplés avec lesdites sour
C09K 11/66 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du germanium, de l'étain ou du plomb
14.
METHOD AND MEANS FOR PREDICTION AND EVALUATION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS
The application discloses methods for predicting the response of a subject diagnosed with rheumatoid arthritis to treatment with an anti-rheumatic drug or for evaluating the response of subject diagnosed with rheumatoid arthritis to treatment with an anti-rheumatic drug. Said methods include detecting antibodies against one or more peptides, antibody-binding fragments, variants or immune reactive peptides thereof in a sample of the subject. Also provided are peptides, antibody-binding fragments, variants or immune reactive peptides, compositions comprising said peptides, antibody-binding fragments, variants or immune reactive peptides thereof and the use of peptides, antibody-binding fragments, variants or immune reactive peptides thereof and compositions.
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
The present invention relates to a microfluidic device comprising (i) a vent [104], which opens upon dissolution of an air-impermeable and water-soluble membrane [102] and (ii) means [105] for increasing hydraulic resistance to liquid flow located upstream of said vent [104]. The invention further relates to use of the device of the invention to partition a volume of liquid and to a method to partition a volume of liquid.
The invention relates to a first fusion protein comprising N-terminally an N-terminal fragment of otoferlin and C-terminally an N-terminal fragment of an intein, and a second fusion protein comprising N-terminally a C-terminal fragment of an intein and C-terminally a C-terminal fragment of intein.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The invention relates to the field of predicting (clinical) response of a cancer patient to a therapy comprising an immune checkpoint blocker or to therapy with an immune checkpoint blocker. In particular enriched pre-therapy levels of intra-tumoral CD8 Temra cells and/or intra-tumoral CXCL10-positive macrophages are markers indicative of a positive response. An alternative pre-therapy marker indicative of a positive response relies on detecting enhanced levels of T cell receptor sharing between intra-tumoral and peripheral CD8 Temra cells. The invention therefore refers to methods of e.g. selecting a patient eligible for therapy comprising an immune checkpoint blocker or for therapy with an immune checkpoint blocker including determining the levels of these markers.
The present invention relates to a computer-implemented method for analysing data obtained by combining a first set (X) of nucleic acid-based count profiles with a second set (Y) of nucleic acid-based count profiles, said second set being obtained in different measurement conditions than said first set. The method comprises: - defining a regularisation function to preserve properties of said first set of nucleic acid-based count profiles, - initialising a data structure, X', derived from said first set of nucleic acid-based count profiles, - determining a projection, Y', of a data structure derived from said second set of nucleic acid-based count profiles on a hypersurface using a function imposing one or more constraints on the data in said data structure derived from said second set of data, - taking an initial value for a regularisation rate, - performing the following substeps: - determining a projection, X'', of data comprised in said data structure, X', on said hypersurface using said function, - performing statistical testing to assess differences between the projected data X'' of said data structure and said projection Y', said statistical testing yielding a plurality of values indicative of a similarity between statistical distributions of X'' and Y', - finding a solution of an optimal transport problem between X'' and Y', so obtaining a transport plan between data points of X'' and data points of Y', - computing said regularisation function for said projection X'', - computing a loss function derived from said solution of said optimal transport problem, said computed regularisation function and said regularisation rate, - updating said data structure, X', using a gradient of said loss function with respect to X', until a reference value obtained from said plurality of values indicative of said similarity reaches a predetermined threshold, and thus a combination of said first set and said second set is obtained wherein bias caused by said different measurement conditions is reduced.
The invention relates to the use of a cellulose with an average degree of Polymerization (DP) below 100 and a crystallinity index below 0.5 as a fermentable dietary fiber in a food composition.
The invention relates to medical devices coated with an antibiotic, wherein the antibiotic is bound to a catechol comprising coating on the device via a pH sensitive boric acid bond, wherein the unbound antibiotic comprises a vicinal diol function.
33 2-), chloride (Cl-44 2-322-), hereinafter called "anions of interest", in any of 1) calcium carbonate or dolomite-based materials, 2) materials comprising calcium carbonate or dolomite, 3) cement based materials or 4) concrete (for instance reinforced concrete). The present invention relates to (i) the use of a photoluminescent active sensor material to sense the anions of interest in alkaline materials, the method of doing it and (iii) a construction of a device to do it.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
C04B 40/00 - Procédés, en général, pour influencer ou modifier les propriétés des compositions pour mortiers, béton ou pierre artificielle, p. ex. leur aptitude à prendre ou à durcir
22.
BENZIMIDAZOLE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
23.
TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
24.
BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.
The disclosure relates to the compounds selectively inhibiting Solute Carrier Family 4 member 4/ Electrogenic Sodium Bicarbonate Cotransporter 1 (SLC4A4/NBCe1). More in particular, said compounds are SLC4A4/NBCe1-inhibiting single domain antibodies, compounds comprising at least one CDR polypeptide of a SLC4A4/NBCe1-inhibiting single domain antibody, and compounds comprising a SLC4A4/NBCe1-inhibiting single domain antibody. Applications of compounds inhibiting SLC4A4/NBCe1 are likewise included.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
27.
HIGH PERFORMANCE AND LOW POWER THREE-DIMENSIONAL STATIC RANDOM ACCESS MEMORY AND METHOD OF FORMING SAME
A three-dimensional (3D) static random access memory (SRAM) cell includes two PU transistors arranged in a first tier, two PD transistors arranged in a second tier positioned above or below the first tier, and two PG transistors arranged in the first or second tier. The transistors can be fin transistors, and each PU and PD transistor can have a first and second number of fins, respectively. The transistors can also be nanosheet-based transistors, and each PU and PD transistor can have a first and a second nanosheet width, respectively.
The invention relates to an in vitro cell culture comprising neuronal cells derived from iPSC, optionally with an NGN2 transgene, astrocytes derived from iPSC with a SOX9 transgene, and oligodendrocytes derived from iPSC with a SOX10 transgene.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A liquefier assembly for use in an extrusion-based additive manufacturing apparatus, includes: a liquefier tube extending between an inlet opening and an outlet opening. The liquefier tube is configured to facilitate the transport of the consumable material through the liquefier assembly between the inlet opening and the outlet opening. A nozzle assembly is coupled to the outlet opening of the liquefier tube and configured to extrude the consumable material in a first direction. A heater block assembly is disposed around at least a portion of the liquefier tube and configured to heat consumable material in the liquefier tube. The first recess exhibits, in section, at least one boundary edge configured to converge thermal radiation in substantially the first direction or a direction having an angle to the first direction.
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present application relates to a glycyrrhizic acid hydrogel with a pH of between 2,5 and 5,0 and comprising an imidazole, for use in the treatment or prevention of a bacterial or fungal infection. The application further relates to a pharmaceutical composition of said hydrogel and a method of treating or preventing a bacterial or fungal infection in an individual comprising the step of administering an effective aammoouunntt of an imidazole in aa glycyrrhizic acid hydrogel, a pharmaceutically acceptable salt or solvate thereof, with a pH of between 2,5 and 5,0.
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A charge sensor circuitry comprises: a detector element configured to generate a charge signal at an internal node; wherein the charge sensor circuitry comprises a first transistor comprising a gate for receiving a first control signal and at least one second transistor comprising a first gate connected to the internal node and a second gate for receiving a second control signal; wherein the charge sensor circuitry is configured to, in a first mode, output a first output signal through the first transistor; wherein the charge sensor circuitry is configured to, in a second mode, reset the internal node through the first transistor and output a second output signal through the at least one second transistor.
H04N 25/778 - Circuits de pixels, p. ex. mémoires, convertisseurs A/N, amplificateurs de pixels, circuits communs ou composants communs comprenant des amplificateurs partagés entre une pluralité de pixels, c.-à-d. qu'au moins une partie de l'amplificateur doit se trouver sur la matrice de capteurs elle-même
The present invention relates to a method to remove polyurethane fibers from a textile product comprising polyurethane fibers and non-polyurethane fibers using a splitting solution comprising a secondary amine, wherein said secondary amine does not contain any primary amine group and wherein each of the two carbon atoms attached to the nitrogen atom in the secondary amine group comprised within said secondary amine form bonds with at least two hydrogen atoms.
C08J 11/28 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation par traitement avec une substance organique par traitement avec des composés organiques contenant de l'azote, du soufre ou du phosphore
The invention relates to method for preparing an inorganic glue from an Fe- comprising material, comprising the step of milling the Fe-comprising material with a liquid, the liquid comprising a compound complexing Fe(II) under alkaline conditions.
C04B 28/00 - Compositions pour mortiers, béton ou pierre artificielle, contenant des liants inorganiques ou contenant le produit de réaction d'un liant inorganique et d'un liant organique, p. ex. contenant des ciments de polycarboxylates
The present application relates to a glycyrrhizic acid hydrogel with a pH of between 2,5 and 5,0, for use in the treatment or prevention of a bacterial infection. The application further relates to a pharmaceutical composition of said hydrogel and a method of treating or preventing a bacterial infection in an individual comprising the step of administering an effective amount of glycyrrhizic acid hydrogel, a pharmaceutically acceptable salt or solvate thereof, with a pH of between 2,5 and 5,0.
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A method for use in radar processing, comprises processing a radar signal captured by a radar receiver, said processing comprising determining, for a scattering object a direction of departure from a radar transmitter to said scattering object; and a direction of arrival at said radar receiver from said scattering object; and calculating a position of said scattering object based on said direction of arrival; said direction of departure; and predetermined position and orientation information of said radar transmitter in relation to said radar receiver, whereby said calculating of said position of said scattering object is unbiased by a time synchronization offset between said radar transmitter and said radar receiver.
G01S 13/42 - Mesure simultanée de la distance et d'autres coordonnées
G01S 7/00 - Détails des systèmes correspondant aux groupes , ,
G01S 13/00 - Systèmes utilisant la réflexion ou la reradiation d'ondes radio, p. ex. systèmes radarSystèmes analogues utilisant la réflexion ou la reradiation d'ondes dont la nature ou la longueur d'onde sont sans importance ou non spécifiées
38.
Biomarkers Predicting Response of Breast Cancer to Immunotherapy
The invention relates to methods of breast tumor analysis relying on the detection of expression levels of specific genes. Such methods find application in, amongst other, predicting the response of a breast cancer patient to immunotherapy or to immunogenic therapy, and in following up such responses. The expression levels of the genes can thus be used in determining which breast cancer patients are most likely to respond to immunotherapy or immunogenic therapy. The genes serving as biomarkers are individually highly performant in predicting the response of a breast tumor to immunotherapy or to immunogenic therapy, but are weak in predicting the response of melanoma to immunotherapy or to immunogenic therapy. Diagnostic kits are likewise part of the invention.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
39.
Heterocycle derivatives for treating TRPM3 mediated disorders
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The present invention relates to antibodies or antibody fragments binding to the human and non-humane primate transferrin receptor. The antibodies herein described can be used as agents to deliver pharmaceutical compounds in or across cells in the process of receptor mediated endocytosis and/or transcytosis. As the transferrin receptor is also present at the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase the delivery of pharmaceutical compounds to the central nervous system.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The invention relates to a method of isolating a lignin fraction from a solution comprising solubilised lignin, the method comprising the steps of adding water to a solution comprising solubilised lignin and a hydrotrope, thereby lowering the hydrotrope concentration, until a part of the lignin becomes insoluble, and isolating the insoluble lignin.
The present invention relates to novel fusion proteins, more specifically chimeric endolysins, and compositions comprising them. Furthermore, the invention relates to polynucleotides, such as nucleic acids and vectors encoding for said chimeric endolysins, as well as host cells comprising these polynucleotides. Also provided by the present invention is a pharmaceutical composition comprising an endolysin of the invention. Finally, the present invention relates to chimeric endolysins, polynucleotides (such as nucleic acid sequences, vectors), host cells, or compositions for use in medicine, in particular veterinary medicine, more in particular for the treatment and/or prevention of infections, in particular mammary gland infections, more in particular udder infections caused by Streptococci and/or Staphylococci.
In accordance with the purpose of the invention, as embodied and broadly described herein, the invention is broadly drawn to the use of an alcoholic medium, for instance methanol medium with an alkaline, for instance an alkali hydroxide, as depolymerization agent without any further addition of organic solvents under microwave action (heating) to achieve almost instantaneous, for instance within 1-13 minutes, for almost 100%, for instance 98-99, 9%, depolymerization of polyethylene terephthalate structures or polycarbonate structures of any suitable shape and morphology such as flakes, fibers, powder, sheet, pellet, spheres, pearls, dendrites, discs or any other three-dimensional shape with a micrometric or millimetric dimension, singly or in combination if these are millinized structures, microsized structures, structures having a thickness up to 5 mm or structures having a maximum dimension of not more than 10 mm.
C08J 11/16 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation par traitement avec une substance inorganique
46.
Yeast Single Nucleotide Polymorphisms for Industrially Relevant Phenotypes
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventeur(s)
Verstrepen, Kevin
Ho, Ping-Wei
Jarosz, Dan
Abrégé
The present invention relates to the field of yeast fermentations. More particularly, the invention relates to mutant alleles useful to engineer industrially relevant traits in yeast.
A method of predicting spectroscopic data pertaining to a chemical processes to be analyzed. The method includes obtaining a feature vector (114; 204) for a set of process variables (111; 211) pertaining to the chemical process, by applying the set of process variables as inputs to a learning structure (112), and generating spectroscopic data (113; 213) in respect of the chemical process, by applying the feature vector as input to a decoder unit (105). The decoder unit is derived from an autoencoder (107) that encodes spectroscopic measurements (102) into code vectors (104). The learning structure generates feature vectors (114; 204) that are predictions of the code vectors (104), provided that the spectroscopic measurement (102) correlates with and relates to the same chemical process as the set of process variables (111; 211).
G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
G01N 21/84 - Systèmes spécialement adaptés à des applications particulières
A composite powder comprising powder particles is disclosed. Each powder particle comprises a core element and a diffusion layer at least partially surrounding the core element. The core element comprises copper, gold or silver and an alloy element capable of forming a nitride, a carbide or a carbonitride. The diffusion layer comprises the alloy element and a nitride, carbide or carbonitride compound. The nitride, carbide or carbonitride compound comprises the alloy element.
The present invention relates to a method for the prediction of the risk of developing preeclampsia in a pregnant human subject, wherein said subject's gestational age is under 140 days, comprising the steps of: (a) measuring in a sample from said subject a plurality of loci-specific DNA methylation levels; (b) deriving from said measurement a DNA methylation profile for said subject (c) comparing said DNA methylation profile to one or more reference DNA methylation profile(s) corresponding to preeclampsia risk group; and (d) assigning on the basis of said comparison said subject to a preeclampsia risk group, thereby predicting the risk of developing preeclampsia in said subject.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
The invention relates to isoquinoline and pyridine based CXCR4 antagonists and their use in the treatment and prevention of viral infections such as HIV.
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
C07D 215/06 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle comportant uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
51.
OLIGONUCLEOTIDES FOR MODULATING SYNAPTOGYRIN-3 EXPRESSION
The invention relates to regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as antisense oligonucleotides. In particular, these synaptogyrin-3 inhibitors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies.
The invention relates to a method for making unilamellar vesicles using Pickering emulsions of aqueous droplets comprising lipids in oil wherein the Pickering emulsions is stabilized by amphiphilic nanoparticles. The invention further relates to the use of the method of the invention to form synthetic cells.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
The invention relates to protein building block named the Self-Assembling Kelch (SAKe) protein. The protein has a stable, symmetric design with readily accessible loops that can be varied in both sequence and length to later bind larger molecules or scaffold a catalytic site.
The invention relates to identification of regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as siRNA molecules. The synaptogyrin-3 inhibitors disclosed herein are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies in particular.
The method of detecting contaminants in a food processing stream whereby materials used in the processing stream are labelled with a fluorescent dye. The accidental presence of such material in the food can be detected by exciting the food with a light source adapted to the excitation peak of the fluorescent dye of the contaminating material and detecting the emission of the fluorescent dye.
The invention relates to methods for the isolation of chitin from arthropod or fungal biomaterial, the method comprising the steps of combining the biomaterial an alcohol or with a mixture of water and an alcohol, incubating the biomaterial to a temperature above 150 °C, and isolating the solid fraction comprising chitin.
The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, thereof, wherein n, q, A1, A2, A3, A4, L1, L2, B1, and B2 have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of a disorder treatable with an exportin 1 (XPO1) inhibitor, such as a proliferative disorder, cancer, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, an allergy, a respiratory disorder, dermatologic syndromes, sun damage, congestive heart failure and hypertrophic cardiomyopathies, wounds, and spinal cord injuries.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
PhascolarctobacteriumVeillonellaEubacteriumAgathobacterLactiplantibacillusAnaerostipesAnaerostipes. Aspects and embodiments described herein may be used in the treatment of joint inflammation, symptoms thereof, and underlying diseases and conditions.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The invention relates to field of neurodegeneration, more particularly to Tau neurotoxicity. The application identifies genes whose reduced expression suppresses pathological Tau mediated effects. These Tau suppressors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies in particular.
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The invention relates to methods of identifying a small molecule that promotes ASB (Ankyrin repeat and SOCS box protein) mediated degradation of a target protein, comprising the step of: - providing in vitro conditions allowing the binding of a small molecule and the protein target, and - determining whether binding of the small molecule to the target protein results in the binding of an ASB protein to the target protein, wherein a small molecule that results in the binding of an ASB protein to a target protein with the small molecule, is a candidate medicinal compound for conditions wherein a target protein is to be degraded.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
62.
SYSTEM AND METHOD FOR VISUAL IMAGE GUIDANCE DURING A MEDICAL PROCEDURE
A system for providing a visualization during a medical procedure on a patient or a simulated medical procedure on a patient model, the system comprising: a. means for receiving imaging data of a first region of the patient's body or the patient model; b. means for receiving tracking data of one or more instruments that are inserted in a second region of the patient's body or the patient model; characterized in that c. the system comprises means for receiving model data of a fourth region of the patient's body or the patient model, and a processing means adapted for co-registering tracking data and model data; d. the system comprises a display for simultaneous visualization of the co-registered data and the imaging data; e. the tracking data comprises three or more tracking points, wherein the three tracking points are not colinear; and/or one or more tracking points and a roll, pitch and yaw angle or a set of Euler angles or a set of quaternions or an angle-axis representation or a rotation matrix or a homogeneous transformation matrix; and/or a point cloud representation, for at least one of the one or more instruments; f. the tracking data is used to determine a position and/or shape and/or orientation of at least one of the one or more instruments; and g. the visualization comprises a representation of the shape and/or the position and/or the orientation of at least one of the one or more instruments; and associated method.
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
G09B 23/28 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la médecine
63.
MIXTURE OF MONOBRANCHED AND POLYBRANCHED FATTY ACIDS
A composition of branched fatty acids or esters thereof and the processes for preparing such compositions and to a process of producing a composition of branched C10-C24 fatty acids or esters thereof with a high portion, at least 70% by weight, of mono and polybranched C10-C24 fatty acids or esters thereof.
C11C 3/12 - Graisses, huiles ou acides gras obtenus par transformation chimique des graisses, huiles ou acides gras, p. ex. ozonolyse par hydrogénation
B01J 29/70 - Zéolites aluminosilicates cristallinesLeurs composés isomorphes de types caractérisés par leur structure spécifique non prévus dans les groupes
A computer-implemented method is provided for modifying a stimulation artefact in a measured electrical response of a subject to a stimulus. The method comprises: i) providing a first and a second signal. The first signal is a signal used as stimulus or a time-dependent signal derived from the stimulus and the second signal is a signal obtained as the measured electrical response to the stimulus; ii) determining a stimulus-response mapping between the first signal and the second signal; iii) identifying a feature of the determined stimulus-response mapping corresponding to the stimulation artefact; iv) determining a predicted electrical response corresponding to the identified feature of the determined stimulus-response mapping; and v) subtracting the predicted electrical response from the second signal to obtain a stimulation artefact modified measured electrical response.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
The invention relates to configurations for MRI or NMR measurements comprising one or more 3D-printed hollow elements, adapted to the shape of an object to be measured wherein in one or more of the 3D-printed elements the wall of the elements is made of a UV-curable electrically non-conducting material forming one or more channels, characterised in that in at least one of the elements with said walls a channel comprises of at least two material plugs of at least two different immiscible materials selected from the group consisting of a dielectric material, an electrically conductive material, and a material with high electrical resistance.
A porous electrode comprising:
an electrically conductive porous network of interconnected wires, and
an electrically conductive support structure,
wherein the network is in direct physical and electrical contact with the support structure, wherein the network has a volumetric surface area of from 2 m2/cm3 to 90 m2/cm3, and a porosity of from 50% to 90%,
wherein a surface of the support structure, facing away from the network, has openings representing from 2 to 90% of its surface area, and wherein the openings are fluidly connected to the pores of the network.
A computer-implemented method for determining a vascular function of a perfusion imaging sequence, includes the steps of: (i) receiving a perfusion imaging sequence comprising a voxel time series for a plurality of voxels; (ii) applying a trained classifier on the perfusion imaging sequence for receiving voxel-wise weights; (iii) receiving voxel-wise weights from the classifier; and (iv) determining the vascular function as the weighted sum of the voxel time series; wherein the classifier is trained by optimizing over the similarity between a predicted vascular function and a ground truth vascular function using a set of examples.
The current disclosure relates to molecule sensing using pore field effect transistor (FET) devices More specifically, the proposed techniques relate to pore (FET) device realizing large bandwidths, high signal strengths and low noise when sensing molecules, which is attained by the unique properties of the device, such as having a wide lumen part of the pore to allow for a sufficiently large electrode, and a narrow aperture part. The disclosure also relates to systems for use thereof, and simulation methods for designing such devices.
Methods, systems, and apparatuses are provided for improving control and efficiency of a compressor system(100). The compressor system includes a controller (106). The controller is configured to predict a future demand for the compressor system, determine an initial sequence based on the predicted future demand, determine an initial set of switching times for the initial sequence, refine the initial switching sequence on the basis of the set of switching times to form a refined switching sequence, iteratively determine a set of switching times for the refined switching sequence and refine the refined switching sequence on the basis of the set of switching times until a final switching sequence and a final set of switching times are obtained, and control operation of the set of components on the basis of the final switching sequence and the final set of switching times.
F04C 23/00 - Combinaisons de plusieurs pompes, chacune étant du type à piston rotatif ou oscillant spécialement adaptées pour les fluides compressiblesInstallations de pompage spécialement adaptées pour les fluides compressiblesPompes multiétagées spécialement adaptées pour les fluides compressibles
F04C 28/02 - Commande, surveillance ou dispositions de sécurité pour les pompes ou les installations de pompage spécialement adaptées pour les fluides compressibles spécialement adaptées pour plusieurs pompes connectées en série ou en parallèle
70.
Imaging Device, an Imaging System and a Method for Wavelength Dependent Imaging
The disclosure relates to an imaging device for wavelength dependent imaging. The imaging device includes a detector having a plurality of light sensitive elements, a plurality of light propagating units, each including: a funnel element for collecting light at a collecting end and propagate the light to a transmitting end; a waveguide for receiving light from the transmitting end at a receiving end and propagating light to a distributing end.
G02B 6/42 - Couplage de guides de lumière avec des éléments opto-électroniques
H04N 23/11 - Caméras ou modules de caméras comprenant des capteurs d'images électroniquesLeur commande pour générer des signaux d'image à partir de différentes longueurs d'onde pour générer des signaux d'image à partir de longueurs d'onde de lumière visible et infrarouge
The invention relates to novel CCR8 antagonists, based on NS-15 as lead structure, were designed and synthesized. To maintain the hydrogen bond potential, focus was on the isosteric replacements of the amide bond. In addition, isosters of the sulfonamide moiety, as well as of the naphthalene scaffold are disclosed.
C07D 295/12 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 498/12 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient trois hétérocycles
C07D 513/12 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient trois hétérocycles
C07C 311/27 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant les atomes de soufre des groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant des cycles
A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
KATHOLIEKE UNIVERSITEIT LEUVEN (Belgique)
CENTRE HOSPITALIER ET UNIVERSITAIRE DE LIMOGES (France)
UNIVERSITE DE LIMOGES (France)
Inventeur(s)
Marquet, Pierre
Labriffe, Marc
Anglicheau, Dany
Gwinner, Wilfried
Naesens, Maarten
Abrégé
The invention relates to a computer-implemented diagnostic method learning for determining clinical interpretation of renal graft alterations by applying a trained machine-learning model and a method for training a model for determining clinical categories based on renal transplant lesions, clinical signs and routine laboratory test results.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
73.
DEVICE AND A METHOD FOR POLARIZATION DEPENDENT IMAGING
According to an aspect of the present inventive concept there is provided a device for polarization dependent imaging, comprising:
a detector comprising light sensitive elements;
a plurality of light propagating units, each comprising a polarization splitter having a receiving end for receiving incident light, and comprising a first and a second waveguide.
According to an aspect of the present inventive concept there is provided a device for polarization dependent imaging, comprising:
a detector comprising light sensitive elements;
a plurality of light propagating units, each comprising a polarization splitter having a receiving end for receiving incident light, and comprising a first and a second waveguide.
The first and second waveguides comprise a first and second portion of the receiving end. The first and second waveguides comprise a first and second distributing end, separate from each other. The polarization splitter is configured to propagate received light to the distributing ends. Each of the portions has an elongated shape such that propagation of light in the waveguides is dependent on the light's linear polarization. The elongated shapes are angled with respect to each other, such that the waveguides are configured to propagate different linear polarization directions.
According to an aspect of the present inventive concept there is provided a device for polarization dependent imaging, comprising:
a detector comprising light sensitive elements;
a plurality of light propagating units, each comprising a polarization splitter having a receiving end for receiving incident light, and comprising a first and a second waveguide.
The first and second waveguides comprise a first and second portion of the receiving end. The first and second waveguides comprise a first and second distributing end, separate from each other. The polarization splitter is configured to propagate received light to the distributing ends. Each of the portions has an elongated shape such that propagation of light in the waveguides is dependent on the light's linear polarization. The elongated shapes are angled with respect to each other, such that the waveguides are configured to propagate different linear polarization directions.
Each light propagating unit is arranged such that light at the first and second distributing ends is output towards a first and second light sensitive element, respectively.
A method for forming a semiconductor device is disclosed. The method includes: forming a first bottom and top channel structures, and second bottom and top channel structures, and a sacrificial gate extending across the channel structures; forming an opening in the sacrificial gate, over the first top channel structure and forming a cut through the first top channel structure; forming a dielectric plug in the cut and the opening; removing the sacrificial gate and subsequently forming an RMG structure comprising a first gate stack on the first bottom channel structure and a second gate stack on the second bottom and top channel structures; forming pairs of S/D structures on the first bottom channel structure, the second bottom channel structure, and the second top channel structure; forming S/D contacts on the S/D structures; forming a trench for a cross-couple contact; and forming the cross-couple contact in the trench.
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 21/8238 - Transistors à effet de champ complémentaires, p.ex. CMOS
H01L 27/092 - Transistors à effet de champ métal-isolant-semi-conducteur complémentaires
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 29/08 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices avec des régions semi-conductrices connectées à une électrode transportant le courant à redresser, amplifier ou commuter, cette électrode faisant partie d'un dispositif à semi-conducteur qui comporte trois électrodes ou plus
H01L 29/423 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative ne transportant pas le courant à redresser, à amplifier ou à commuter
H01L 29/775 - Transistors à effet de champ avec un canal à gaz de porteurs de charge à une dimension, p.ex. FET à fil quantique
Example embodiments relate to methods for forming a semiconductor device. One example method includes forming a device structure on a substrate, where the device structure includes a device layer stack that includes a bottom device sub-stack that includes at least one bottom channel layer and a top device sub-stack that includes at least one top channel layer, a sacrificial gate structure extending across the device layer stack, and bottom source/drain structures on opposite ends of at least one bottom channel layer. The method also includes forming an opening exposing the top device sub-stack, wherein forming the opening includes etching the sacrificial gate structure, forming a cut through the top device sub-stack by etching back the top device sub-stack from the opening and, subsequent to forming the cut, forming a functional gate stack on the at least one bottom channel layer.
The present disclosure relates to static random access memory (SRAM). In particular, the disclosure provides a stacked SRAM cell, and a method for fabricating the stacked SRAM cell. The stacked SRAM cell comprises two first transistor structures and two second transistor structures, which form a pair of cross-coupled inverters, an comprises one or two pass gate (PG) transistor structures. Further, the stacked SRAM cell comprises a first power rail and/or a second power rail arranged above the transistor structures, wherein the first power rail is connected by respective first vias to the first transistor structures from above, and/or the second power rail is connected by respective second vias to the second transistor structures from above. The SRAM cell also comprises one or two bit lines arranged below the PG transistor structures. Each bit line is connected by a respective third via to one PG transistor structure from below.
The invention relates to the in vitro use of a di- or tri carboxylic acid with a chain length of between 15 and 23 carbon atoms, such as agaric acids in preventing formation, decreasing formation or delaying formation of a biofilm by bacteria on abiotic surfaces.
A01N 37/02 - Acides carboxyliques saturés ou leurs thio-analoguesLeurs dérivés
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
The present invention provides a flexible ultrasound transducer for an ultrasound monitoring system for examining a curved object. The ultrasound transducer comprises an integrated circuit structure and a multi-layered structure, said multi-layered structure comprising an array of ultrasound transducing elements arranged in a first layer structure and configured for generating ultrasonic energy propagating along a main transducer axis Z and an array of control circuits arranged in a second layer structure, and wherein the array of control circuits and the integrated circuit structure are configured for operating the array of ultrasound transducing elements in said first layer structure, Further, the multi-layered structure comprises at least one flexible layer arranged so that the bending flexibility of the multi-layered structure permits the ultrasound transducer to form a continuous contact with said curved object during operation.
B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
B06B 1/02 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
The present disclosure relates to biosensor field effect transistors (bio-FETs) and biosensor devices. The disclosure proposes a biosensor device comprising one or more bio-FETs and one or more readout circuits, wherein each readout circuit is connected to a source node of one bio-FET. Each readout circuit is configured to generate a readout signal based on a bias current of the bio-FET. Further, each readout circuit is configured to calibrate the bio-FET it is connected to. To this end, each readout circuit is configured to generate a calibration signal based on a current difference between the bias current of the bio-FET and a reference current, and to control a bias of the source node of the bio-FET according to the calibration signal.
A computer-implemented prediction method (100) for the control of industry-scale batch distillation processes and a distillation apparatus (400) controlled by this method are disclosed. The methods comprises building a hybrid model (103) by combining a phenomenological model of the batch distillation process with a first and a second statistical model. The phenomenological model includes an energy balancing constraint (301-2) that uses a liquid enthalpy coefficient (h) and a heat transfer coefficient (U) as inputs. The first and second statistical model predict dynamic changes of the liquid enthalpy coefficient and the heat transfer coefficient respectively. The hybrid model is trained with experimental data relating to at least one measurable process variable of the process and a performance indicator of the process is predicted based on the trained hybrid model. A control output relating to a control variable of the batch distillation process may be generated (107) if the predicted performance indicator (PPV) deviates from a measured value (MPV) of the performance indicator.
G05B 13/04 - Systèmes de commande adaptatifs, c.-à-d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
G05B 17/02 - Systèmes impliquant l'usage de modèles ou de simulateurs desdits systèmes électriques
A method for forming a semiconductor device is provided. The method includes: forming, over a substrate, a stacked transistor structure comprising: a bottom channel structure and a top channel structure, a gate structure extending across the bottom and top channel structures, a first and a second bottom S/D structure on the bottom channel structure, and a first and a second top S/D structure on the top channel structure; forming a first and a second bottom S/D contact on the first and the second bottom S/D structures; forming a contact isolation layer capping the first and second bottom S/D contacts, and covering the capped first and second bottom S/D contacts with an ILD layer; forming a first contact trench; forming a second contact trench; and forming a first top S/D contact.
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 21/8238 - Transistors à effet de champ complémentaires, p.ex. CMOS
H01L 27/092 - Transistors à effet de champ métal-isolant-semi-conducteur complémentaires
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 29/417 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative transportant le courant à redresser, à amplifier ou à commuter
H01L 29/423 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative ne transportant pas le courant à redresser, à amplifier ou à commuter
H01L 29/775 - Transistors à effet de champ avec un canal à gaz de porteurs de charge à une dimension, p.ex. FET à fil quantique
A system is provided for joint communication and radar sensing. The system includes at least one communication transmitter unit configured to transmit at least one communication pilot signal, at least one radar transmitter unit configured to transmit at least one radar pilot signal, a control unit configured to schedule the transmission of the at least one communication transmitter unit and/or the at least one radar transmitter unit using a time delay, and at least one receiver unit configured to receive the at least one radar pilot signal with the time delay with respect to the at least one communication pilot signal. A method of using the system for joint communication and radar sensing is also provided.
A set of methods of processing a set of Kikuchi diffraction patterns acquired for a series of incident positions of an electron beam on a sample material are described. One such method involves the steps of identifying a first pattern in the set containing a matrix signal and suspected of additionally containing a secondary phase signal; identifying a second pattern close to the first pattern which contains a matrix signal without containing a secondary phase signal; modifying the contrast and intensity of either the first pattern or the second pattern, the modification depending on a relative property of the first and second patterns, resulting in a modified first or second pattern; and obtaining a secondary phase signal pattern by either i) if the first pattern was modified, subtracting the original second pattern from the modified first pattern; or ii) if the second pattern was modified, subtracting the modified second pattern from the original first pattern.
In one aspect, a device includes a threshold switch formed of a mixture. The mixture includes a composition of three chemical elements of: from 0.15 to 0.70 parts by mole of one or two chemical elements selected from Si, Ge, and Sn, from 0.15 to 0.70 parts by mole of S, and optionally from 0.05 to 0.45 parts by mole of one chemical element selected from N, Sb, and P. Each of the three chemical elements is present in an amount of at least 0.05 parts by mole. The mixture also includes at most 0.10 parts by mole of chemical elements different from the three chemical elements. The parts by mole of the mixture add up to 1.00.
H10N 70/00 - Dispositifs à l’état solide n’ayant pas de barrières de potentiel, spécialement adaptés au redressement, à l'amplification, à la production d'oscillations ou à la commutation
H10B 63/00 - Dispositifs de mémoire par changement de résistance, p. ex. dispositifs RAM résistifs [ReRAM]
In one aspect, a device includes a threshold switch formed of a mixture. The mixture includes at least 0.90 parts by mole of a composition of three or four chemical elements of: from 0.20 to 0.70 parts by mole of Si, from 0.05 to 0.60 parts by mole of Te, and from 0.05 to 0.60 parts by mole of S, P, or a mixture of S and P. The mixture also includes at most 0.10 parts by mole of optional other chemical elements different from Si, Te, S, and P. The parts by mole of the mixture add up to 1.00.
H10N 70/00 - Dispositifs à l’état solide n’ayant pas de barrières de potentiel, spécialement adaptés au redressement, à l'amplification, à la production d'oscillations ou à la commutation
H10B 63/00 - Dispositifs de mémoire par changement de résistance, p. ex. dispositifs RAM résistifs [ReRAM]
H10N 70/20 - Dispositifs de commutation multistables, p. ex. memristors
Disclosed herein are yeast strains and derivatives thereof. as well as compositions comprising the yeast strains for use in ethanol manufacture. The disclosure also relates to processes for producing ethanol from biomass using the yeast strains and compositions. In particular, the yeast strains produce lower glycerol and higher ethanol, and have a higher temperature tolerance and higher fermentation rate than strains and products currently used in ethanol production processes.
C12P 7/10 - Éthanol en tant que produit chimique et non en tant que boisson alcoolique préparé comme sous-produit, ou préparé à partir d'un substrat constitué par des déchets ou par des matières cellulosiques d'un substrat constitué par des matières cellulosiques
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) (Espagne)
Inventeur(s)
Rousseau, Frederic
Schymkowitz, Joost
Orlando, Gabriele
Serrano Pubul, Luis
Abrégé
The present methods and systems generally relate to the biomedical field and relate to subfields of computational biology and bioinformatics. More, specifically the invention provides an artificial intelligence algorithm which can predict the stability of proteins and protein complexes.
The disclosure relates to a capacitive memory structure (10), comprising: a substrate (11); a first metallic layer (12) on the substrate; a ferroelectric material layer (13) on the first metallic layer (12); wherein the ferroelectric material layer (13) is electrically excitable to two polarization states, each polarization state representing a memory state of the capacitive memory structure (10). The capacitive memory structure (10) further comprises a second metallic layer (14) on the ferroelectric material layer (13); wherein the first metallic layer (12) and the second metallic layer (14) have different work functions.
H10B 53/30 - Dispositifs RAM ferro-électrique [FeRAM] comprenant des condensateurs ferro-électriques de mémoire caractérisés par la région noyau de mémoire
H01L 21/28 - Fabrication des électrodes sur les corps semi-conducteurs par emploi de procédés ou d'appareils non couverts par les groupes
91.
Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
The present invention relates to a process for recovering platinum group metals from a feed containing one or more precursor compounds of one or more platinum group metal ions, wherein the process comprises the steps of (i) supplying to a cathode compartment of an electrochemical cell equipped with a cathode comprising a gas diffusion electrode with a porous electrochemically active material, the feed containing the one or more precursor compounds to form a liquid phase in the cathode compartment, (ii) supplying a CO2 containing gas to the cathode compartment, (iii) applying a potential to the cathode which is such as to cause electrochemical reduction of the CO2 to CO, (iv) and recovering from the liquid phase precipitated particles of the one or more platinum group metals in clemental form.
Method of removing one or more solvent soluble additives from a polymer comprising less than 40 wt % polyvinylchloride or from a mixture of polymers comprising less than 40 wt % polyvinylchloride, the method comprising the steps of: a) dissolving said polymer or mixture of polymers comprising said one or more solvent soluble additives in a solvent or a solvent mixture that dissolves said polymer or polymer mixture, and that dissolves as well said one of more additives, b) filtrating the solution comprising the dissolved polymer or polymer mixture and the one or more dissolved additives over a solvent resistant membrane, whereby the dissolved polymer is retained by the membrane and the one or more solvent soluble additives permeate through the membrane.
A conductive oxygen barrier layer, a stack comprising the conductive oxygen barrier layer, and method of forming the stack for a semiconductor device are provided. The method includes providing a semiconductor substrate, forming a conductive electrode layer on the semiconductor substrate, and forming a conductive oxygen barrier layer on the electrode layer, and then forming at least one complex oxide layer on the oxygen barrier layer. The forming of the oxygen barrier layer includes forming a silicon layer on the electrode layer and a platinum layer on the silicon layer. The forming of the at least one complex oxide layer comprises heating to a temperature in a range of 500-700° C. or higher, which results in the oxygen barrier layer comprising an alloy of platinum and silicon.
The present invention relates to a cementitious composition comprising one or more cementitious material(s); and a silver-containing, crosslinked polymer, wherein the crosslinked polymer is a covalently crosslinked polymer, and preferably wherein said silver-containing, crosslinked polymer comprises -A ⊝Ag ⊕groups; wherein A ⊝ is an anion, preferably a carboxylate anion or a sulphonate anion. The present invention further relates to a silver-containing covalently crosslinked polymer, as comprised in said cementitious composition, and various uses of such compositions and polymers for preparing concrete materials with improved properties or for coating concrete structures.
C04B 28/02 - Compositions pour mortiers, béton ou pierre artificielle, contenant des liants inorganiques ou contenant le produit de réaction d'un liant inorganique et d'un liant organique, p. ex. contenant des ciments de polycarboxylates contenant des ciments hydrauliques autres que ceux de sulfate de calcium
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
A radio frequency system (1) for characterizing one or more groups of individuals (2) in a space (3), comprising: − a transmitter (101) transmitting two waveforms (11;12); − a receiver (102) configured to: o receive echoes (21;22) of the waveforms (11;12); o generate a range profile comprising a range distribution of the echoes (21;22); o generate filtered range profiles by filtering static clutter; − a processing unit (103) configured to: o range normalize the filtered range profiles; o generate an updated spatial map or an updated combined range profile after thresholding; o determine a total power between two distances in the updated spatial map or in the updated combined range profile; o generate therefrom one or more power metrics relating the total power to a density and/or an activity of the groups of individuals (2) in the space (3).
G01S 7/41 - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe utilisant l'analyse du signal d'écho pour la caractérisation de la cibleSignature de cibleSurface équivalente de cible
G01S 13/88 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques
98.
METHOD OF DETERMINING PROCESS PARAMETERS FOR LASER POWDER BED FUSION ADDITIVE MANUFACTURING
The present invention relates to a method for controlling a device for additive manufacturing arranged to perform an LPBF process. The method comprises determining a set of control parameters to control said device for additive manufacturing by - providing a set of thermophysical properties of the powder to be used, a set of parameters specific to the device including a laser spot size, and a target layer thickness for a layer to be produced in the LPBF process; - modelling a laser melt pool as a half ellipsoid shape with melt pool depth d and melt pool width w, wherein consecutive laser passes have a separation x, and determining a value for the separation x which yields a maximum amount of added net molten material in a single laser pass; - expressing the determined value of the separation x as a function of melt pool depth; - solving the separation expression for laser power and scan speed subject to the target layer thickness and the Plateau-Rayleigh criterion, by deriving from the set of parameters specific to the device a plurality of pairs of laser power and scan speed, obtaining for each pair melt the pool width w, melt pool length l and melt pool aspect ratio R from the melt pool model comprising the set of parameters including the laser spot size and the thermophysical properties, calculating d as d = R.w, and finding a pair of laser power and scan speed values that satisfies the Plateau-Rayleigh criterion and the target layer thickness, - deriving from the obtained values for laser power and scan speed the set of control parameters to control the device.
B33Y 50/02 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
B22F 10/37 - Commande ou régulation des opérations des caractéristiques du lit de poudre, p. ex. de la densité
B22F 10/38 - Commande ou régulation des opérations pour obtenir des caractéristiques spécifiques du produit, p. ex. le lissage de la surface, la densité, la porosité ou des structures creuses
B22F 10/36 - Commande ou régulation des opérations des paramètres du faisceau d’énergie
The present invention relates to the field of microbiology, in particular to the field of bacterial antibiotic resistance. more particularly to the field of resistance to beta-lactam inhibitors. The invention provides non-natural compounds which induce the aggregation of beta-lactamases, particularly beta-lactamases of class A. In addition, the invention provides combination therapies and pharmaceutical compositions between the non-natural molecules and beta-lactam antibiotics.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
The invention relates to methods for preparing dicarbamylated and/or polycarbamylated compounds from polyurethane, the method comprising the steps of: (i) contacting a material comprising polyurethane with a solution comprising a monofunctional alcohol and a catalyst, wherein the catalyst is Lewis acid catalyst and/or a tertiary amine catalyst and (ii) heating said solution comprising said polyurethane, said monofunctional alcohol and said catalyst, resulting in a chemolytic splitting of said polyurethane in dicarbamylated or polycarbamylated compounds.
C08J 11/24 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation par traitement avec une substance organique par traitement avec des composés organiques contenant de l'oxygène contenant des groupes hydroxyle
